Prevalence-and gender-specific immune response to opportunistic infections in HIV-infected patients in lesotho

Sexually Transmitted Diseases

Volumn 37, Issue 7, 2010, Pages 454-459

  Rabenau, Holger F ^a   Lennemann, Tessa ^a   Kircher, Claudia ^a   Gürtler, Lutz ^a   Staszewski, Schlomo ^a   Preiser, Wolfgang ^b   McPherson, Piet ^c   Allwinn, Regina ^a   Doerr, Hans Wilhelm ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c Karabong Clinic Mafeteng Government Hospital   (Lesotho)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BACTERIUM ANTIBODY; VIRUS ANTIBODY;

ADULT; AGED; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; CYTOMEGALOVIRUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS A VIRUS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; PREVALENCE; SEROPREVALENCE; SEX RATIO; TREPONEMA PALLIDUM; AIDS-RELATED OPPORTUNISTIC INFECTIONS; BLOOD; COMPLICATION; HERPES GENITALIS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGY; LESOTHO; MICROBIOLOGY; MIDDLE AGED; SEX DIFFERENCE; SYPHILIS; VIROLOGY; VIRUS DISEASES;

ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; CD4 LYMPHOCYTE COUNT; FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HIV; HIV INFECTIONS; HUMANS; LESOTHO; MALE; MIDDLE AGED; PREVALENCE; SEROEPIDEMIOLOGIC STUDIES; SEX FACTORS; SYPHILIS; TREPONEMA PALLIDUM; VIRUS DISEASES;

EID: 77954084167     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/OLQ.0b013e3181cfcc2b     Document Type: Article

References (48)

1. UNAIDS/WHO Working Group on Global HIV/AIDS and STI Surveillance. Epidemiological Fact Sheet on HIV and AIDS: Core data on epidemiology and response: Lesotho, 2008 Update. Geneva, Switzerland: UNAIDS/WHO Working Group on Global HIV/AIDS and STI Surveillance, 2008.
2. Kravitz JD, Mandel R, Petersen EA, et al. Human immunodeficiency virus seroprevalence in an occupational cohort in a South African community. Arch Intern Med 1995; 155:1601-1604.
3. Nagot N, Ouedraogo A, Foulongne V, et al. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med 2007; 356:790-799.
4. Smith JS, Robinson NJ. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: A global review. Infect Dis 2002; 186(suppl 1):S3-S28.
5. Doerr HW, Braun R, Munk K. Human cytomegalovirus infection: Recent developments in diagnosis and epidemiology. Klin Wochenschr 1985; 63:241-251.
6. Hamprecht K, Maschmann J, Vochem M, et al. Epidemiology of transmission of cytomegalovirus from mother to preterm infant by breastfeeding. Lancet 2001; 357:513-518.
7. Enzensberger R, Braun W, July C, et al. Prevalence of antibodies to human herpes viruses and hepatitis B virus in patients at different stages of human immunodeficiency virus (HIV) infection. Infection 1991; 19:140-145.
8. Adjei A, Armah H, Narter-Olaga E. Seroprevalence of cytomeg-alovirus among some voluntary blood donors at the 37 military hospital, Accra, Ghana. Ghana Med J 2006; 40:99-104.
9. Modi AA, Feld JJ. Viral hepatitis and HIV in Africa. AIDS Rev 2007; 9:25-39.
10. Lok A, McMahon B. Chronic hepatitis B. Hepatology 2001; 34:1225-1241.
11. CDC Website. Geographic Distribution of Hepatitis B. Available at: http://www.cdc.gov/ncidod/diseases/hepatitis/slideset/hep-b/slide-9.htm. Accessed September 10, 2006.
12. WHO Hepatitis B Fact-sheet. Available at: http://www.who.int/mediacentre/ factsheets/fs204/en/. Accessed September 10, 2006.
13. Gisselquist D, Perrin L, Minkin S. Parallel and overlapping HIV and blood borne hepatitis epidemics in Africa. Int J STD AIDS 2004; 15:145-152.
14. Majori S, Baldo V, Tommasi I, et al. Hepatitis A, B, and C infection in a community of sub-Saharan immigrants living in Verona (Italy). J Travel Med 2008; 15:323-327.
15. Kambarami RA, Manyame B, Macq J. Syphilis in Murewa District, Zimbabwe: An old problem that rages on. Cent Afr J Med 1998; 44:229-232.
16. Myer L, Abdool Karim SS, Lombard C, et al. Treatment of maternal syphilis in rural South Africa: Effect of multiple doses of benzathine penicillin on pregnancy loss. Trop Med Int Health 2004; 9:1216-1221.
17. Shaw M, van der Sande M, West B, et al. Prevalence of herpes simplex type 2 and syphilis serology among young adults in a rural Gambian community. Sex Transm Infect 2001; 77:358-365.
18. Williams BG, Taljaard D, Campbell CM, et al. Changing patterns of knowledge, reported behaviour and sexually transmitted infections in a South African gold mining community. AIDS 2003; 17:2099-2107.
19. Salama II, Samy SM, Shaaban FA, et al. Seroprevalence of hepatitis A among children with different socioeconomic status in Cairo. East Mediterr Health J 2007; 13:1256-1264.
20. Atina JO, Ogutu EO, Hardison WG, et al. Prevalence of hepatitis A, B, C and human immunodeficiency virus seropositivity among patients with acute icteric hepatitis at the Kenyatta National Hospital, Nairobi. East Afr Med J 2004; 81:183-187.
21. Vardas E, Ross MH, Sharp G, et al. Viral hepatitis in South African healthcare workers at increased risk of occupational exposure to blood borne viruses. J Hosp Infect 2002; 50:6-12.
22. Stroffolini T, Chiaramonte M, Ngatchu T, et al. A high degree of exposure to hepatitis A virus infection in urban children in Cameroon. Microbiologia 1991; 14:199-203.
23. Werner GT, Frösner GG, Fresenius K. Prevalence of serological hepatitis A and B markers in a rural area of northern Zaire. Am J Trop Med Hyg 1985; 34:620-624.
24. Otegbayo JA, Taiwo BO, Akingbola TS, et al. Prevalence of hepatitis B and C seropositivity in a Nigerian cohort of HIV-infected patients. Ann Hepatol 2008; 7:152-156.
25. Ejele O, Nwauche C, Erhabor O. The prevalence of hepatitis B surface antigenemia in HIV-positive patients in the Niger Delta Nigeria. Niger J Med 2004; 13:175-179.
26. Uneke C, Ogbu O, Inyama P, et al. Prevalence of hepatitis-B surface antigen among blood donors and HIV-infected patients in Jos, Nigeria. Mem Inst Oswaldo Cruz 2005; 100:13-16.
27. Hoffmann CJ, Charalambous S, Martin DJ, et al. Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis 2008; 47:1479-1485.
28. Lukhwareni A, Burnett RJ, Selabe SG, et al. Increased detection of HBV DNA in HBsAg-positive and HBsAg-negative South African HIV/AIDS patients enrolling for highly active antiretroviral therapy at a Tertiary Hospital. J Med Virol 2009; 81:406-412.
29. Mphahlele MJ, Lukhwareni A, Burnett RJ, et al. High risk of occult hepatitis B virus infection in HIV-positive patients from South Africa. J Clin Virol 2006; 35:14-20.
30. Stroffolini T, Ngatchu T, Chiaramonte M, et al. Prevalence of cytomegalovirus seropositivity in an urban childhood population in Cameroon. New Microbiol 1993; 16:83-85.
31. Adjei AA, Armah HB, Gbagbo F, et al. Seroprevalence of HHV-8, CMV, and EBV among the general population in Ghana, West Africa. BMC Infect Dis 2008; 8:111.
32. Parboosing R, Paruk I, Lalloo UG. Hepatitis C virus seropositivity in a South African Cohort of HIV co-infected, ARV naïve patients is associated with renal insufficiency and increased mortality. J Med Virol 2008; 80:1530-1536.
33. Potter D, Goldenberg RL, Read JS, et al. Correlates of syphilis seroreactivity among pregnant women: The HIVNET 024 Trial in Malawi, Tanzania, and Zambia. Sex Transm Dis 2006; 33:604-609.
34. Rabenau HF, Buxbaum S, Preiser W, et al. Seroprevalence of herpes simplex virus types 1 and type 2 in the Frankfurt am Main area, Germany. Med Microbiol Immunol 2002; 190:153-160.
35. Howard M, Sellors JW, Jang D, et al. Regional distribution of antibodies to herpes simplex virus type 1 (HSV-1) and HSV-2 in men and women in Ontario, Canada J Clin Mcrobiol 2003; 41:84-89.
36. Glynn JR, Crampin AC, Ngwira BM, et al. Herpes simplex virus type 2 trends in relation to the HIV epidemic in northern Malawi. Sex Transm Infect 2008; 84:356-360.
37. Buxbaum S, Geers M, Gross G, et al. Epidemiology of herpes simplex virus types 1 and 2 in Germany: What has changed? Med Mcrobiol Immunol 2003; 192:177-181.
38. Gupta R, Warren T, Wald A. Genital herpes. Lancet 2007; 370: 2127-2137.
39. Watson-Jones D, Weiss HA, Rusizoka M, et al. Risk factors for herpes simplex virus type 2 and HIV among women at high risk in northwestern Tanzania: Preparing for an HSV-2 intervention trial. J Acquir Immun Defic Syndr 2007; 46:631-642.
40. Benjamin RJ, Busch MP, Fang CT, et al. Human immunodeficiency virus-1 infection correlates strongly with herpes simplex virus-2 (genital herpes) seropositivity in South African and United States blood donations. Transfusion 2008; 48:295-303.
41. Brown JM, Wald A, Hubbard A, et al. Incident and prevalent herpes simplex type 2 infection increases risk of HIV acquisition among women in Uganda and Zimbabwe. AIDS 2007; 21:2356-2357.
42. Weiss HA, Buve A, Robinson NJ, et al. The epidemiology of HSV-2 infection and its association with HIV infection in four urban African populations. AIDS 2001; 15(suppl 4):S97-S108. (Pubitemid 32913009)
43. Dannenmaier B, Alle W, Hoferer EW, et al. Incidences of antibodies to hepatitis B, herpes simplex and cytomegalovirus in prostitutes. Zentralbl Bakteriol Mkrobiol Hyg A 1985; 259:275-283.
44. Ampofo W, Torpey K, Mukadi YD, et al. Normal CD4+ T lymphocyte levels in HIV seronegative individuals in the Manya/Yilo Krobo communities in the Eastern region of Ghana. Viral Immunol 2006; 19:260-266.
45. Koelle DM, Corey L. Recent progress in herpes simplex virus immu-nobiology and vaccine research. Clin Mcrobiol Rev 2003; 16:96-113.
46. Strauss SE, Wald R, Kost RG, et al. Immunotherapy of recurrent genital herpes with recombinant herpes simplex type 2 glycoprotein B and D: Results of a placebo-controlled vaccine trial. J Infect Dis 1997; 176:1129-1134.
47. Kaushic C, Ashkar AA, Reid LA, et al. Progesterone increases susceptibility and decreases immune response to genital herpes infection. J Virol 2003; 77:4558-4565.
48. Gillgrass AE, Askar AA, Rosenthal KL, et al. Prolonged exposure to progesterone prevents induction of protective mucosal responses following intravaginal immunization with attenuated herpes simplex virus type 2. J Virol 2003; 77:9845-9851.